ReviewHematology. American Society of Hematology. Education Program2018
The new tool "
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- A 25-year evolution of systemic mastocytosis to mast cell leukemia: Cutaneous clues.JAAD case reports · 2026Article
- Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.The journal of allergy and clinical immunology. Global · 2026Article
- Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.Blood advances · 2024Article
- Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis.Proceedings (Baylor University. Medical Center) · 2023Article
- Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.Hematology. American Society of Hematology. Education Program · 2022Review
- Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.Biomedicines · 2022Review
- Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.Cancers · 2022Review
- CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition inCancers · 2022Article
- Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.International journal of molecular sciences · 2022Review
- Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis.Acta dermato-venereologica · 2021Article
- Avapritinib in the Treatment of Systemic Mastocytosis: an Update.Current hematologic malignancy reports · 2021Review
- Vascular endothelial growth factors and angiopoietins as new players in mastocytosis.Clinical and experimental medicine · 2021Article
- Avapritinib for Systemic Mastocytosis.Expert review of hematology · 2021Article
- Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.International journal of molecular sciences · 2021Review
- Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis.Annals of hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastocytosis is a rare disease characterized by KIT-driven expansion and accumulation of neoplastic mast cells in various tissues. Although mediator symptoms related to mast cell activation can impose a symptom burden in cutaneous disease and across the spectrum of systemic mastocytosis subtypes, the presence of an associated hematologic neoplasm and/or organ damage denotes advanced disease and the potential for increased morbidity and mortality. In addition to the revised 2016 World Health Organization classification of mastocytosis, a new diagnostic and treatment toolkit, tethered to enhanced molecular characterization and monitoring, is poised to transform the management of patients with advanced systemic mastocytosis (advSM). Although the efficacy of midostaurin and novel selective KIT D816V inhibitors, such as avapritinib (BLU-285), have validated KIT as a therapeutic target, the clinical and biologic heterogeneity of advSM requires that we reimagine the blueprint for tackling these diseases and use tools that move beyond KIT-centric approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.